Periodic Table of MND Research

SympWatch (Sw)

For the first time, you can watch a selection of full presentations from our 30th Symposium in Perth, Australia, across our Periodic Table. To help guide you through the research talks, SympWatch videos include useful ‘pop ups’ explaining some of the scientific language used by the researchers. Take a moment to watch the videos already released:

Perth (Pe)

SympWatch

Watch the full Welcome to Symposium talk with the Welcome to Country performance from the Opening Session at the 30th Symposium in Perth 2019:

MND Australia & MNDAWA (Au)

MND Australia will be hosting the 30th International Symposium on MND/ALS this year in partnership with MNDAWA (Motor Neurone Disease Association of Western Australia).

MND Australia is a non-profit organisation that is the national voice representing all Australians who share the vision of a world without MND. Drawing on 35 years of experience, MND Australia works with a national network of State MND Associations to advocate, educate and raise awareness. Their goal is to empower Australians impacted by MND to live better for longer. Until there is a cure, MND Australia’s research arm, the MND Research Institute of Australia, will promote and fund the best research with the greatest chance of making MND treatable.

MNDAWA is a non-profit organisation that is the specialist support organisation in Western Australia. It is committed to working with people living with MND, their carers and families, ensuring they will not be alone.

Global Walk to D’feet MND (Gw)

The first ever Global Walk to D’Feet MND was held as part of the 30th International Symposium on ALS/MND this year to raise awareness of ALS/MND. The 5km, wheelchair accessible, walk occurred in the evening of the first day of the Symposium (Wednesday 4 December) along Perth’s picturesque Swan River. Following the walk, Cytokinetics warmly invited all delegates who took part in the walk to join them as they honoured and recognised the contributions of advocacy groups worldwide with local Australian barbecue food and refreshments served in the Summer Garden at the Perth Convention and Exhibition Centre.

We had an amazing turnout of over 400 people all wearing their respective country’s ALS/MND association or institution T-shirts!

Awards (Aw)

SympWatch

The 11^th Paulo Gontijo Award internationally recognised Dr Laura Ferraiuolo, from the Sheffield Institute of Translational Neuroscience (SITraN), for her investigation into the role of astrocytes (star-shaped cells that support neurons), particularly their secreted particles, as well as for her continued dedication to understand and find a treatment for MND.

Read summary of her work here, or watch Dr Ferraiuolo present the findings of her winning paper at the Symposium last year:

Satellite meetings (Sm)

Whilst the main Symposium runs over three days, Wednesday to Friday, there are also several satellite meetings in the days before as well as during the Symposium itself. The International Alliance of ALS/MND Associations organises meetings to serve the broader ALS/MND community: The Annual International Alliance Meeting, on the 1-2 December 2019 and Allied Professionals Forum on the 3 December.

The Annual Alliance Meeting is attended by representatives of ALS/MND associations from around the world and provides the opportunity for these associations to meet and share knowledge of supporting people living with ALS/MND. It is also an opportunity for representatives from around the world to discuss developments and planning from their organisations, patient care and funding, and the role and activities of the Alliance and its Board of Directors.  View the 2019 agenda here. You can view the scientific update from the Scientific Advisory Council here:

People with MND (Pw)

People living with MND, their carers and families are at the heart of everything we do, and our reason for organising the Symposium every year. Whilst the event is aimed primarily at scientists and healthcare professionals, there is an opportunity for people with MND to attend, via the Patient Fellows Programme managed by the ALS Therapeutic Development Institute (ALSTDI). This allows some people with MND to be funded to attend the Symposium and then share their experiences via an article or social media.

At the Symposium

Poster presentations (Po)

Researchers who would like to present at the Symposium must submit an abstract – an overview of their research and findings. A Programme Committee then decides who will be given the chance to present to an audience from the stage (oral presentations) and who will be offered a poster – the chance to display their work in the form of a poster at a dedicated session. Some submissions do not get offered either.

This year, as well as having 110 speakers, we also have over 420 poster presentations. Giving researchers the opportunity to talk about their work with the wider MND research community with a poster, means that even more exciting and innovative work can be shared than would be possible with just oral presentations. The poster sessions encourage networking and collaboration, bringing together researchers, clinicians, neurologists and other healthcare professionals. The poster sessions also give researchers who are still in the early stages of their work, and don’t yet have any results, to present in the Work in Progress section.

You can read all the abstracts online. Where we have mentioned a specific poster in a tile on the periodic table, we have included the code for that poster, for example RNM-03. This tells you that the abstract for that poster can be found in the Respiratory and Nutrition Management section and it is abstract number three.

Platform presenters (Pp)

Researchers who would like to present at the Symposium must submit an abstract – an overview of their research and findings. A Programme Committee then decides who will be given the chance to present to an audience from the stage – platform presentations and who will be offered a poster – the chance to display their work in the form of a poster at a dedicated session. Some submissions do not get offered either.

Platform presentations are prestigious, and Perth will hear 110 speakers over the three days of the Symposium. These talks will be split between three sessions; biomedical (A), clinical (B), and alternative mixed (C). Each session is organised by specific themes such as genetics, clinical trials or neuroimaging. See the full programme for this year’s Symposium.

Alongside these presentations we also invite several plenary (keynote) speakers who are the world experts in their respective fields. Their talks complement the Symposium sessions by providing an overview of a variety of topics across the ALS/MND research and clinical management spectrum. See this year’s plenary speakers.

You can read all the accepted abstracts online. Please note, the page may take a couple of minutes to load. All platform presentations have a code beginning with ‘C’ followed by a number (e.g. C50). This will help you locate the specific abstract mentioned throughout the periodic table topics.

Plenary speakers (Pl)

Every year we invite a number of plenary speakers who are experts in their respective fields. Their talks complement the Symposium sessions by providing a coherent overview on a variety of topics across the ALS/MND research and clinical management spectrum.

This year’s plenary speakers are:

• Dr Jeffrey J Iliff – University of Washington School of Medicine (USA)
  ‘Glymphatic system dysfunction as a driver of protein mis-aggregation in neurodegenerative disease’
  Session 1: Joint Opening Session (C1)
• Professor Martin Turner – University of Oxford (UK)
  ‘The biomarker challenge: What is it, and are we there yet?’
  Session 1: Joint Opening Session (C2)
• Professor Justin Yerbury – University of Wollongong (Australia)
  ‘The fine balance of proteostasis and its implications for ALS
  Session 2A: Proteostasis/Proteotoxicity (C3)
  (You can read about Prof Yerbury’s work in this blog article)
• Associate Professor Kenneth Rodgers – University of Technology Sydney (Australia)
  ‘Non-protein amino acids and neurodegenerative disease’
  Session 2A: Proteostasis/Proteotoxicity (C7)
• Dr Hiroshi Nishimune – University of Kansas School of Medicine (USA)
  ‘Neuromuscular degeneration in ALS and SMA’
  Session 3A: Synaptic Pathology (C19)
• Professor Nortina Shahrizaila – University of Malaya
  ‘ALS phenotypes, demographics and clinical management in Asia’
  Session 3B: Demographics and clinical features (C23)
• Professor Naomi Wray – University of Queensland (Australia)
  ‘Future direction in ALS genomics’
  Session 3C: Genomics (C27)
• Professor Don W Cleveland – University of California, San Diego (USA)
  ‘Designer drug therapy for human neurodegenerative disease’
  Session 4A: Therapeutic Strategies (C32)
• Professor Steven Finkbeiner – the J David Gladstone Institutes and University of California (San Francisco (USA)
  ‘iPSC-derived models for genetic and compound screening in ALS’
  Session 4A: Therapeutic Strategies (C33)
• Professor Erik P Pioro – Section of ALS & Related Disorders Cleveland Clinic (USA)
  ‘Pseudobulbar effect in ALS: Not (only) a laughing matter
  Session 4B: Non-motor Symptoms (C37)
• Professor Samar Aoun – Perron Institute for Neurological and Translational Science and La Trobe University (Australia)
  ‘Supporting MND family carers from diagnosis to bereavement: The palliative approach to care’
  Session 5B: Carer and Family Support (C52)
• Dr Melinda S Kavanaugh – University of Wisconsin – Milwaukee (USA)
  ‘Research and support for young caregivers in families with ALS’
  Session 5B: Carer and Family Support (C53)
• Dr Gen Sobue – Nagoya University Graduate School of Medicine (Japan)
  ‘Lessons from SBMA study: Pathophysiology, clinical characteristics and treatment strategies’
  Session 5C: The Spectrum of Motor Neuron Disorders (C56)
• Professor Shigeki Kuzuhara – Suzuka University of Medical Science (Japan)
  ‘ALS-PDC of the Kii Peninsula, Japan: Clinical and neuropathological features and epidemiology’
  Session 5C: The Spectrum of Motor Neuron Disorders (C57)
• Dr Arindra Nath – National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, Maryland (USA)
  ‘Investigating the role of endogenous retroviruses in ALS’
  Session 6A: Human Cell Biology and Pathology (C60)
• Professor Luc Deliens – Ghent University and Vrije Universiteit Brussel (Belgium)
  ‘Palliative care and healthcare utilisation at the end of life in people with ALS’
  Session 6B: Palliative Care (C65)
• Dr Julian Grosskreutz – University Hospital Jena (Germany)
  ‘Is ALS a network disease?’
  Session 6C: Neuroimaging (C68)
• Dr Susan E Mathers – Calvary Health Care Bethlehem (Australia)
  ‘Progressive neurological diseases: Modelling care’
  Session 7B: Improving Care Practice (C77)
• Associate Professor Bradley Turner – University of Melbourne (Australia)
  ‘Mouse models of ALS: Past, present and future’
  Session 8A: Disease Models (C90)
• Professor Capucine Morélot-Panzini – Pitié-Salpétrière University Hospital–Sorbonne University (France)
  ‘The multidimensional nature of respiratory failure in ALS’
  Session 9B: Respiratory Support (C105)
• Professor David J Berlowitz – University of Melbourne (Australia)
  ‘The management of disordered breathing in MND’
  Session 9B: Respiratory Support (C106)
• Associate Professor Thomas J Oxley – University of Melbourne (Australia)
  ‘The dawn of brain computer interfaces’
  Session 10: Joint Closing Session (C110)

Healthcare professionals (Hp)

As well as researchers, many healthcare professionals attend the Symposium to help expand their existing knowledge of MND. All fields are represented at the Symposium from respiratory experts to physiotherapists. It is a chance for them to hear innovative talks from experts in their field from nutritional support to quality of life and learn about new techniques and ways to improve their practice.

Helping to educate healthcare professionals is a priority for the MND Association as this will help those affected by MND have a better multi-disciplinary care plan, as well as improving their quality of life. As part of this education the Association runs conferences, study days and online learning for professionals on a range of topics. Find out more about these events for healthcare professionals.

View this year’s Allied Professional Forum (APF) agenda here. Our Head of Education and Information, Rachel Boothman, joint-hosted the session and gave a presentation on Let’s talk about end of life in ALS/MND-a masterclass for professionals. You can watch recordings from the APF here.

Watch the APF Award Announcement to Rachael Marsden here:

Neuromuscular junction (Nj)

The neuromuscular junction (NMJ) is a chemical synapse formed by the contact between a motor neuron and a muscle fibre. It is at the NMJ that a motor neuron can transmit a signal to the muscle fibre, causing muscle contraction. Muscles require innervation (literally meaning ‘to put nerves into’, so when nerves go into muscle fibre, they innervate that muscle) to function and even just to maintain muscle tone to avoid the muscle from wasting away. In the NMJ nerves from the central nervous system and peripheral nervous system are linked and work together with muscles. Motor neurons release a neurotransmitter called acetylcholine which crosses the synapse at the NMJ and binds to receptors on the muscle fibre which results in a muscle contraction.

Studies have revealed the important involvement of muscles and NMJs in the initial stages of MND. But where does motor neuron degeneration begin? Both ‘dying-forward’ (where the motor neurons degenerate by glutamate excitotoxicity) or ‘dying-back’ (in which motor neuron degeneration starts at the NMJ and progresses toward the cell body) processes have been suggested and it is possible that both processes occur independently of each other. Regardless, it is acknowledged that degeneration to the NMJ, leading to skeletal muscle wasting, is a key point in MND clinical symptom onset and disease progression.

Mitochondria (Mt)

Mitochondria are organelles – specialised units within a cell that have a specific function – and are essential for a variety of cellular processes including providing energy for the cell (bioenergetics), calcium homeostasis – which regulates the concentration of calcium ions in the fluid outside the cell, lipid biosynthesis – the production of lipids (fats) which are the main form of stored energy in most organisms, and apoptosis – normal and controlled cell death.

Mitochondrial dysfunction is a common feature of many neurodegenerative diseases including MND. Disruption of mitochondrial structure, bioenergetics and stabilisation of calcium ions has been widely reported in people with MND and models of the disease and has been suggested to be directly involved in the development of MND.

Modelling MND (Mo)

In order to understand what goes wrong in MND, researchers need to study ‘something’ that, to all intents and purposes, mimics the biology of the disease. Ideally that ‘something’  has to be readily available, tangible, accessible, and available with a large enough number of samples so that any findings can be reproduced and confirmed.

There is currently no way to visualise all the complex interactions that happen in MND. For example, observing all of the biology of motor neurones in living people is impossible, and so researchers use models of the disease.

There are generally three types of models that are used to research MND:

• In vitro (meaning ‘in the glass’) models use isolated cells in a lab dish, with the most widely used being induced pluripotent stem cells (iPSCs). These are skin cells taken from people with MND that are transformed into stem cells – cells with the potential to turn into different types of cells, including motor neurones.
• In vivo (meaning ‘within the living’) models include testing in living organisms, with the most widely used animals being zebrafish, fruitflies, worms or mice.
• In silico (meaning “in silicon” as in silicon microchips) modelling, while not as common, is used to perform a computer simulation.

Retroviruses (Rv)

There is evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in MND. Endogenous means ‘within the body’ and HERVs are genes that are found in our genome. Our genome contains all our genetic material, in the form of DNA, and is stored in the nucleus of all cells in our body. HERV-K has been directly linked to MND and has been found in the brain tissue of people with the disease.

For a long time, HERVs were believed to be ‘fossil viruses’ or ‘junk’ DNA, rendered inactive as they became defective or mutated as they were passed through generations over millions of years. They comprise up to 5-8% of the human genome and there is now evidence to suggest that they are not inactive.

HERVs are a type of gene called a retrotransposon which can ‘jump’ from one part of the genome to another. They contain DNA and use a ‘copy and paste’ mechanism which enables them to integrate themselves into the genome at a different place. In a process called transcription, the viral DNA sequences are converted into RNA, a short section of genetic code which, in normal cells, encodes for the proteins that make up the building blocks of our bodies. In virus-infected cells, the RNA is moved out of the nucleus into the cytoplasm. Using an enzyme called reverse transcriptase, the RNA is then ‘copied’ to make identical DNA sequences, moved back into the nucleus and ‘pasted’ back into the genome near another gene. This can cause disease if too many copies of the gene are made.

Using antiretroviral therapies, it may be possible to stop the malformed proteins being made.

Nutrition (Nu)

Eating and drinking form an emotive part of our lives, bringing us comfort and pleasure. Being nourished is not just about calories – for most of us, the enjoyment of food and flavour is incredibly important to quality of life. Knowing how to maintain this when living with MND can make a huge difference.

With MND, the way a person eats and drinks may need to be adapted to help them get the nutrition and fluids their body needs. They may experience difficulties with chewing and swallowing (see tile Sw for more information on swallowing), problems with hand and arm control, reduced mobility (making food preparation difficult) and fatigue, which can make the effort of eating and drinking tiring in itself.

Weight loss in MND is associated with faster disease progression and shorter survival and has several possible causes. These include loss of appetite, difficult in swallowing and hypermetabolism, which is an increase in the rate at which energy is burned – even though mobility may be limited, a person ‘burns off’ more calories than they consume.

Respiration (Re)

MND can affect the way a person breathes by weakening the muscles that control breathing. Although this cannot be reversed, there are treatments that can help reduce symptoms such as disturbed sleep, fatigue and anxiety, and enable the person to breathe more effectively.

When breathing becomes weaker a machine may be used to support breathing. This is known as assisted ventilation. There are two types of assisted ventilation: non-invasive ventilation, where a machine supports breathing by boosting the intake of normal air through a mask, and tracheostomy ventilation, where a tube is inserted into the windpipe through the front of the neck, which enables a ventilator to support breathing.

The use of ventilation may not be suitable for everyone. If appropriate, it may help to relieve breathing problems but will not stop the progress of the disease.

Swallowing (Sl)

Swallowing problems, known as dysphagia, affect at least two-thirds of people with MND during their illness. This is due to a weakening of the muscles in the mouth and throat. If MND affects a person’s ability to swallow, it becomes harder for them to eat and drink. As a result, they are likely to experience dehydration and weight loss.

At the Symposium

Our platform presentations included a talk about a pilot trial to assess the feasibility and effect of swallowing exercises and diet in people with MND. Presented by Professor Victoria Flood, this work followed promising results from two trials looking at exercises for the strengthening of the expiratory muscles, and a study using a mouse model in which 20% of calories came from extra virgin olive oil, leading to increased survival rate, improved motor co-ordination and less muscle atrophy compared to controls (C97).

Physical exercise (Ph)

The stories about MND and physical activity that make it into the media feature prominent sports people who have been very active for a number of years. While this is good for raising awareness of the disease, it also raises concerns for people living with MND.

Most concerns fall into two categories: did the amount of physical activity I undertook before my diagnosis cause my MND and can I continue with physical activity after my diagnosis, or will this make my MND worse?

Physical activity ranges from gentle exercise, like walking, to more vigorous daily activity like working out at a gym, to the levels achieved by professional sportspeople and elite athletes.

Exercise is widely recommended to the general population due to its benefits to health and wellbeing. It improves the cardiovascular, respiratory, musculoskeletal, and endocrine functions and leads to psychological wellbeing. Many people with MND specifically ask whether they can safely continue to exercise regularly without fear of accelerating their disease. At present, there is no firm evidence that exercise exerts a harmful effect, although avoidance of very strenuous activity would seem to be sensible. Low-grade, managed exercise programmes may even be of benefit.

For many people with MND, exercise played an integral role in their pre-diagnosis lives. A wish to continue exercising, in the hope it will have positive effects on endurance and strength, is understandable. While pre-diagnosis exercise is likely to have involved aerobic training and strengthening programmes, research has shown that moderate exercise can slow functional decline whereas high intensity training can be detrimental.

Caregiver support (Cs)

When someone is diagnosed with MND, the changes affect not only the person with the disease but also those close to them. Becoming a carer for someone with MND can be very challenging and, over time, the level of care needed will increase – sometimes rapidly.

Supporting someone with MND can often feel emotionally overwhelming but there can be many positive emotions, such as satisfaction when a task or challenge is successfully completed, especially if this has involved both the carer and the person with MND. It is important that the carer takes time to look after their own needs, even if this feels impossible when facing the challenges of supporting someone with MND.

At the Symposium

Palliative care (Pc)

This section talks openly about death and end of life decisions.

The aim of hospice and palliative care is to give the best possible quality of life with a life-shortening illness. For maximum benefit to people with MND, this type of care is recommended from the point of diagnosis onward.

Palliative care refers to specialised care services that focus on quality of life and symptom control when an individual has an illness that can’t be cured. This includes practical help, medication to ease symptoms and support for the individual and their family. Palliative care isn’t just for end of life. It may be given earlier in a person’s illness in conjunction with other therapies treating the condition.

Palliative care is of utmost importance in MND and focusing on managing symptoms and improving quality of life of people living with the disease is a priority of healthcare professionals. Because of the nature of the disease, it is important for those affected by MND to know about the symptoms they should expect as the disease progresses, and how best to manage them. Research is always ongoing to find out how best to manage symptoms and when to utilise life-sustaining measures.

Cognition & behaviour (Cb)

Up to half of people with MND experience changes to how they think and behave, and these affect people in different ways. For some they will have little effect on daily life, while others will need significant day-to-day support. In a small number of cases, people with MND develop frontotemporal dementia (FTD).

People with MND may experience changes to their thinking and learning, language and communication, and behaviour and emotions. It may become more difficult for them to make and carry out plans, process information and solve problems. They may find it harder to recognise words when reading or writing, have difficulty spelling or find it hard to follow conversations. They might also begin to lack enthusiasm, find it difficult to manage emotions and behave inappropriately in social situations.

If a person is affected by FTD they will experience symptoms similar to those already described but with greater severity. With FTD, memory is not usually affected although it may appear that it is due to difficulties with concentration and taking in new information.

Augmentative & alternative comms (Ac)

Augmentative and alternative communication (AAC) tools are vital for people living with MND. As their disease progresses, they may experience slurred speech or even completely lose the ability to speak (dystharia). To ensure that people with MND can continue to have a voice in making decisions regarding their care, technology can facilitate communication when speech is impaired. AACs can be as simple as using hand gestures, facial expression and writing, but can also include using high tech devices to communicate.

At the Symposium

A comprehensive review of the literature available on AAC in MND was carried out by researchers in Brazil with the aim of identifying types of AAC and its purpose, to assess how it might be best used by people with complex communication needs (COG-14).

Justin Yerbury (Jy)

SympWatch

Watch Prof Justin Yerbury discuss the fine balance of proteostasis (the process that regulates proteins within the cell) and its implication for ALS (C3) from the 30th International Symposium in Perth 2019:

Genetics (Ge)

SympWatch

Professor Naomi Wray from The University of Queensland, Australia, gave a talk on the future directions of ALS genomics (C27) with a comparison to other diseases and disorders.

Watch the full presentation:

Lifestyle & environment (Le)

The causes of MND are still not fully understood. Around 90% of people with MND have a sporadic form of the disease – when the disease appears for no apparent reason and with no known familial link. Sporadic MND is thought be caused by a combination of genetic, environmental and lifestyle influences.

Exposure to these factors has been extensively studied. This is known as epidemiology. Epidemiological studies have identified possible links with prior exposure to mechanical and/or electrical trauma, military service, high levels of physical activity, agricultural chemicals and a variety of heavy metals. However, these are all only suspected contributory risk factors and the evidence from studies is often circumstantial or conflicting and offers no clear conclusions.

Understanding the causes and mechanisms of motor neurone degeneration is essential to the development of new treatments. Only by understanding what goes wrong in MND can scientists identify potential drug targets and other therapies.

Inflammation (In)

Although MND is not a disease of the immune system, there is evidence from studies of patients that the levels of some types of immune cells in the blood can play a role in the speed at which the disease progresses.

Neuroinflammation is commonly seen in neurodegenerative diseases, including MND, and animal studies have shown active roles of glial (support) and immune cells in the development of MND.

Neuroinflammation is an inflammatory process thought to originate primarily from central nervous system (CNS) cell types such as microglia and astrocytes. Both cells have pro- and anti-inflammatory functions meaning that they can offer protection against cell injury or can become destructive.

For example, astrocytes are key homeostatic cells (they have the ability to maintain internal stability) that play numerous supportive roles in maintaining the brain environment. In MND, astrocytes change their shape and molecular expression patterns, and are referred to as reactive or activated astrocytes. Reactive astrocytes in MND lose their beneficial functions and gain detrimental roles. In addition, interactions between motor neurons and astrocytes are impaired in MND.

Microbiome (Mi)

Recent studies have found that microbes living in our gut (microbiome) might have an effect on the rest of the body, including the immune and nervous systems. It is possible that the microbiome may be able to communicate with and affect the immune cells in the brain and spinal cord, the microglia.

Microglia have a naturally protective effect on motor neurones and the rest of the nervous system. Therefore, if the microbiome has the potential to affect the way microglia are behaving in the brain and motor neurones of people with MND (and other neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease), the microbiome could become an important treatment target.

Researchers are currently focusing on the possible differences in the gut microbes of people with MND compared to people without the disease, in order to establish the possible connection between gut microbes and MND (and other neurodegenerative diseases).

Motor neurone disorders (Md)

It has long been debated whether ALS/MND is one disease, or whether we should look at it as a collection of multiple conditions with similar symptoms and disease mechanisms. We are observing a large amount of variation in terms of speed of disease progression, length of survival, type of onset (bulbar or limb), absence/presence of frontotemporal dementia and its degree, as well as cause of the disease (e.g. involvement of specific genes).

This is especially important when investigating the effectiveness of a new drug in clinical trials, which might not work in the same way across all MND subgroups. A good example is the drug lithium, which was found not to be effective in treating MND, until the data re-analysis found that there was an improvement in people with a specific genetic variation (UNC13A).

Delivering diagnosis (Dd)

Breaking the news of the diagnosis of MND can be challenging for most healthcare professionals. As well as this, most people affected by MND are dissatisfied with their experience. Could there be room for improvement in the practice of delivering diagnosis and policies? More integration across care sectors and a more person-centred approach to care from the beginning could be the way forward.

At the Symposium

Delivering diagnosis will especially be discussed for healthcare professionals in two talks and several poster presentations at the Symposium this year. This includes a talk on modelling care for progressive neurological diseases (C57) and a discussion on the gap between standards and actual practice of delivering diagnosis (C78).

A poster presentation within Theme 13: Clinical management and support will discuss the diagnostic experience in MND through a UK survey (CMS-04).

Progression & prognosis (Pr)

A prognosis is defined as a likely course of a medical condition. ALS/MND is a progressive and fatal neurodegenerative disease, with an average life expectancy of two to three years. However, individual prognosis can be highly variable – from weeks to decades. Several prognostic factors are known, such as site of onset (bulbar or limb), age at symptom onset, delay from onset to diagnosis, and the use of riluzole and non-invasive ventilation (NIV).

While we wait for an established tissue biomarker (a signature of a biological change), measures of clinical progression are currently the standard for monitoring disease progression. The most widely used measure is the revised ALS Functional Rating Scale (ALSFRS-R), which is a 12-item clinical chart assessing patient’s functional abilities. Each item asks about specific abilities (such as speech, swallowing, dressing, or walking) and is rated on a 5-point scale from ‘0’ severe disability) to ‘4’ (normal functioning). A cumulative score gives a physician a considered view on the person’s disease status (where 48 marks means normal functioning).

Other measures focus on more specific symptoms of the disease, including motor neurone loss, reduced breathing ability, or assessment of behaviour and thinking abilities.

Biomarkers (Bi)

SympWatch

In the opening session, Prof Martin Turner gave a plenary talk on the biomarker challenge (C2). A lack of biomarkers has prevented therapy development from reproducing the model of trials that has been so successful in other diseases such as cancer. With a decade of global research focused on MND biomarkers, are we there yet?

Watch the full presentation:

Telehealth (Te)

Telehealth, or telemedicine, involves the use of technology to allow healthcare professionals to monitor an individual’s health and deliver care remotely. For example, they could assist in the diagnosis and management of a condition. The ultimate goals of using this technology are to increase access to care for people, decrease the frequency of clinical visits and reduce clinical costs.

For people with reduced mobility, telehealth means no long commutes to short, but critical, assessments and no waiting around. From previous studies, people taking part in remote assessments expressed higher satisfaction with the overall care they were given and appreciated remaining in the comfort of their own homes. People living long distances away from services or with increasing disease related disability are usually most likely to utilise Telehealth.

Clinical trials (Ct)

Clinical trials are research studies in human volunteers that determine whether potential treatments are safe and effective. All clinical trials have strict guidelines about who can take part (factors that allow inclusion criteria). Clinical trials are usually conducted in four progressive phases which check for safety and efficacy, establish the correct dosage and method of delivery, and assess the drug’s ability to treat the condition it is designed for.

Clinical trials take many years to complete and are often extremely costly. At any stage the drug can be deemed too dangerous, or inefficient, to take into the next phase. To speed up the process, clinical trials are beginning to incorporate a biomarker element (a biological characteristic) into their design. Monitoring levels of specific biomarkers during a trial will help establish if the drug or intervention being tested is influencing disease progression. Researchers are also looking to ‘repurpose’ drugs that have showed an effect for other diseases and have already been shown to be safe in humans, as potential treatments for MND.

Platform trials (Pt)

There is an urgent need for innovative clinical trial designs to accelerate the drug development process to test awaiting candidate therapies and develop new therapeutics for ALS/MND. A potential solution is an adaptive platform trial which allows multiple drugs to be tested and evaluated for each drug’s efficacy simultaneously, and with fewer participants required.

TRICALS, the world’s largest network of trained specialised ALS centres, has just launched to collect and combine patient data in the UK and Europe. The clinical trial design, which will start with lithium, will be expanded and improved, targeted more precisely, and carried out more quickly.

At the Symposium

Gene therapy (Gt)

There are a growing number of genes which have been associated with MND. The most common of these are SOD1, TARDBP (TDP-43), FUS and C9ORF72. Other extremely rare genes have also been identified to be causative. There are currently no treatments to prevent the effects of the gene damage that is being passed from one generation to another. However, research is underway to find such treatments. An emerging innovative approach has been gene therapy.

Gene therapy is designed to introduce genetic material into cells to alter how faulty/missing genes work in order to correct genetic disorders. It is expected at the very least to alleviate the symptoms and slow the progression of MND. Hopefully, gene therapy could even prevent the disease when a faulty gene is diagnosed and treated at an early-enough stage.

Brain-computer interface (Bc)

A brain-computer interface (BCI) is a direct communication pathway between an enhanced or wired brain and an external device.

Research has shown that brain signals can be recorded using electrical sensors implanted onto the brain. Signals could be used by the individuals to control assistive technology (e.g. spelling devices) to help with daily life, just by thinking. Implanting these electrical sensors often requires open brain surgery. Although this is technically not considered a treatment yet, implantation of a BCI system in patients could have potential to restore communication in people with severe paralysis, similar to the procedure utilised for implantation of cardiac pacemakers. A new medical device and surgical technique has been developed to allow implantation without open brain surgery.

At the Symposium

CuATSM (Cu)

SympWatch

Associate Professor Peter Crouch from Melbourne University discussed the relevance of the candidate MND drug, Copper ATSM, to sporadic MND, and the therapeutic potential for this compound to extend to all forms of MND and other neurodegenerative disorders (C36).

Watch the full presentation:

Drug screening (Ds)

Before a drug can be tested in clinical trials (in humans), it first must be examined in a lab to provide an insight into its mechanism (how it is likely to work in the body), safety, and preliminary effectiveness. These studies can be done in cells in a lab dish (in vitro), in animals (in vivo), or using computer modelling (in silico).

While there is only a limited number of clinical trials, there are many compounds currently being investigated that could have the potential to be developed into ALS/MND treatments.

In general, only an extremely small proportion of compounds tested in pre-clinical studies get to the final drug approval stage, reflecting the rigorous and strict process assuring that only safe drugs of good quality are tested in clinical trials and approved.